Pliant Therapeutics Inc. (PLRX) Adds David Pyott to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors
January 12, 2021 8:00 AM ESTSOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Dr. David Pyott, former Chairman and Chief Executive Officer of Allergan, to Pliants Board of Directors. Â
David is an accomplished international pharmaceutical executive whose extensive experience in building companies will be invaluable at this stage of Pliants development, said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer... More
